| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.7M | — | +1952.2% |
| R&D Expense | $7.1M | — | -0.1% |
| SG&A Expense | $43.7M | — | +137.5% |
| Interest Expense | $21.7M | — | +361.7% |
| Pre-tax Income | -$248.4M | — | -291.4% |
| Income Tax | $1.2M | — | +595.8% |
| Net Income | -$191.0M | — | -317.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.03B | +29.7% | +246.7% |
| Short-term Investments | $2.80B | +40.0% | +228.0% |
| Accounts Receivable | $27.5M | -27.2% | — |
| Inventory | $16.8M | +39.6% | — |
| Current Assets | $3.15B | +28.2% | +252.4% |
| Total Assets | $6.05B | +20.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$48.1M | — | -68.4% |
| Capital Expenditures | $261.6M | — | +117.2% |
| Investing Cash Flow | -$379.3M | — | -214.9% |
| Financing Cash Flow | $1.11B | — | +142.5% |
| Free Cash Flow | -$309.7M | — | -107.8% |
| +341.8% |
| Current Liabilities | $170.7M | +13.5% | +102.7% |
| Long-term Debt | $2.96B | +34.2% | +541.1% |
| Total Liabilities | $3.39B | +29.3% | +462.3% |
| Stockholders' Equity | $2.66B | +11.2% | +247.1% |